143 related articles for article (PubMed ID: 17332320)
1. The Asn418-linked N-glycan of ErbB3 plays a crucial role in preventing spontaneous heterodimerization and tumor promotion.
Yokoe S; Takahashi M; Asahi M; Lee SH; Li W; Osumi D; Miyoshi E; Taniguchi N
Cancer Res; 2007 Mar; 67(5):1935-42. PubMed ID: 17332320
[TBL] [Abstract][Full Text] [Related]
2. N-glycan of ErbB family plays a crucial role in dimer formation and tumor promotion.
Takahashi M; Yokoe S; Asahi M; Lee SH; Li W; Osumi D; Miyoshi E; Taniguchi N
Biochim Biophys Acta; 2008 Mar; 1780(3):520-4. PubMed ID: 18036567
[TBL] [Abstract][Full Text] [Related]
3. Neuregulin-1 only induces trans-phosphorylation between ErbB receptor heterodimer partners.
Li Z; Mei Y; Liu X; Zhou M
Cell Signal; 2007 Mar; 19(3):466-71. PubMed ID: 16978839
[TBL] [Abstract][Full Text] [Related]
4. Selective hormone-dependent repression of estrogen receptor beta by a p38-activated ErbB2/ErbB3 pathway.
St-Laurent V; Sanchez M; Charbonneau C; Tremblay A
J Steroid Biochem Mol Biol; 2005 Feb; 94(1-3):23-37. PubMed ID: 15862947
[TBL] [Abstract][Full Text] [Related]
5. Cooperative signaling of ErbB3 and ErbB2 in neoplastic transformation and human mammary carcinomas.
Alimandi M; Romano A; Curia MC; Muraro R; Fedi P; Aaronson SA; Di Fiore PP; Kraus MH
Oncogene; 1995 May; 10(9):1813-21. PubMed ID: 7538656
[TBL] [Abstract][Full Text] [Related]
6. Truncated ErbB2 receptor (p95ErbB2) is regulated by heregulin through heterodimer formation with ErbB3 yet remains sensitive to the dual EGFR/ErbB2 kinase inhibitor GW572016.
Xia W; Liu LH; Ho P; Spector NL
Oncogene; 2004 Jan; 23(3):646-53. PubMed ID: 14737100
[TBL] [Abstract][Full Text] [Related]
7. c-Src modulates ErbB2 and ErbB3 heterocomplex formation and function.
Ishizawar RC; Miyake T; Parsons SJ
Oncogene; 2007 May; 26(24):3503-10. PubMed ID: 17173075
[TBL] [Abstract][Full Text] [Related]
8. Growth stimulation of non-small cell lung cancer cell lines by antibody against epidermal growth factor receptor promoting formation of ErbB2/ErbB3 heterodimers.
Maegawa M; Takeuchi K; Funakoshi E; Kawasaki K; Nishio K; Shimizu N; Ito F
Mol Cancer Res; 2007 Apr; 5(4):393-401. PubMed ID: 17426253
[TBL] [Abstract][Full Text] [Related]
9. Suppression of heregulin β signaling by the single N-glycan deletion mutant of soluble ErbB3 protein.
Takahashi M; Hasegawa Y; Ikeda Y; Wada Y; Tajiri M; Ariki S; Takamiya R; Nishitani C; Araki M; Yamaguchi Y; Taniguchi N; Kuroki Y
J Biol Chem; 2013 Nov; 288(46):32910-21. PubMed ID: 24097984
[TBL] [Abstract][Full Text] [Related]
10. Epidermal growth factor mutant with wild-type affinity for both ErbB1 and ErbB3.
Wingens M; Jacobs-Oomen S; van der Woning SP; Stortelers C; van Zoelen EJ
Biochemistry; 2006 Apr; 45(14):4703-10. PubMed ID: 16584205
[TBL] [Abstract][Full Text] [Related]
11. Roles of mitogen-activated protein kinase and phosphoinositide 3'-kinase in ErbB2/ErbB3 coreceptor-mediated heregulin signaling.
Vijapurkar U; Kim MS; Koland JG
Exp Cell Res; 2003 Apr; 284(2):291-302. PubMed ID: 12651161
[TBL] [Abstract][Full Text] [Related]
12. Expression of epidermal growth factor receptor or ErbB3 facilitates geldanamycin-induced down-regulation of ErbB2.
Pedersen NM; Breen K; Rødland MS; Haslekås C; Stang E; Madshus IH
Mol Cancer Res; 2009 Feb; 7(2):275-84. PubMed ID: 19208749
[TBL] [Abstract][Full Text] [Related]
13. Interaction of integrin alpha(6)beta(4) with ErbB3 and implication in heregulin-induced ErbB3/ErbB2-mediated DNA synthesis.
Kawano S; Mizutani K; Miyata M; Ikeda W; Takai Y
Genes Cells; 2010 Sep; 15(9):995-1001. PubMed ID: 20695903
[TBL] [Abstract][Full Text] [Related]
14. Constitutive activation of neuregulin/ERBB3 signaling pathway in clear cell sarcoma of soft tissue.
Schaefer KL; Brachwitz K; Braun Y; Diallo R; Wai DH; Zahn S; Schneider DT; Kuhnen C; Vollmann A; Brockhoff G; Gabbert HE; Poremba C
Neoplasia; 2006 Jul; 8(7):613-22. PubMed ID: 16867224
[TBL] [Abstract][Full Text] [Related]
15. The single N-glycan deletion mutant of soluble ErbB3 protein attenuates heregulin β1-induced tumor progression by blocking of the HIF-1 and Nrf2 pathway.
Takamiya R; Takahashi M; Uehara Y; Ariki S; Hashimoto J; Hasegawa Y; Kuroki Y
Biochem Biophys Res Commun; 2014 Nov; 454(3):364-8. PubMed ID: 25451255
[TBL] [Abstract][Full Text] [Related]
16. Oligomers of ERBB3 have two distinct interfaces that differ in their sensitivity to disruption by heregulin.
Kani K; Warren CM; Kaddis CS; Loo JA; Landgraf R
J Biol Chem; 2005 Mar; 280(9):8238-47. PubMed ID: 15611073
[TBL] [Abstract][Full Text] [Related]
17. The extracellular domains of ErbB3 retain high ligand binding affinity at endosome pH and in the locked conformation.
Kani K; Park E; Landgraf R
Biochemistry; 2005 Dec; 44(48):15842-57. PubMed ID: 16313187
[TBL] [Abstract][Full Text] [Related]
18. Expression of heregulin alpha, erbB2, and erbB3 and their influences on proliferation of gastric epithelial cells.
Noguchi H; Sakamoto C; Wada K; Akamatsu T; Uchida T; Tatsuguchi A; Matsui H; Fukui H; Fujimori T; Kasuga M
Gastroenterology; 1999 Nov; 117(5):1119-27. PubMed ID: 10535875
[TBL] [Abstract][Full Text] [Related]
19. ErbB3-dependent motility and intravasation in breast cancer metastasis.
Xue C; Liang F; Mahmood R; Vuolo M; Wyckoff J; Qian H; Tsai KL; Kim M; Locker J; Zhang ZY; Segall JE
Cancer Res; 2006 Feb; 66(3):1418-26. PubMed ID: 16452197
[TBL] [Abstract][Full Text] [Related]
20. Pertuzumab counteracts the inhibitory effect of ErbB2 on degradation of ErbB3.
Sak MM; Szymanska M; Bertelsen V; Hasmann M; Madshus IH; Stang E
Carcinogenesis; 2013 Sep; 34(9):2031-8. PubMed ID: 23698633
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]